Denali Therapeutics Inc.
DNLI
$20.57
-$0.13-0.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.02% | -18.39% | -25.34% | -30.62% | 3.95% |
| Total Depreciation and Amortization | 44.41% | 70.21% | 103.71% | 48.57% | 145.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.75% | 42.32% | 53.88% | 1,005.08% | -13.66% |
| Change in Net Operating Assets | -52.48% | -120.50% | 385.41% | -38.73% | 80.46% |
| Cash from Operations | -17.71% | -81.43% | 17.45% | -15.71% | 15.15% |
| Capital Expenditure | 70.07% | 135.48% | 10.61% | -136.19% | -127.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -87.43% | -42.12% | 56.95% | 105.28% | 135.51% |
| Cash from Investing | -87.94% | -38.25% | 60.23% | 104.14% | 135.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.81% | 94.33% | -- | -- | -- |
| Issuance of Common Stock | 22,053.38% | -89.31% | -39.95% | -99.88% | -11.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,709.72% | 95.81% | -75.98% | -100.75% | -188.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.62% | -414.87% | 497.38% | -75.08% | 503.37% |